Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Illumina, Inc. - Common Stock (NQ:ILMN)

236.80 -53.26 (-18.36%)
Delayed Quote Updated: 3:33 PM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Illumina, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
News headline image
PacBio (PACB) Q2 Earnings Report Preview: What To Look For
Genomics company Pacific Biosciences of California (NASDAQ:PACB) will be announcing earnings results this Thursday afternoon. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
Earnings To Watch: 10x Genomics (TXG) Reports Q2 Results Tomorrow
Biotech company 10x Genomics (NASDAQ:TXG) will be reporting results this Thursday after market hours. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence Economy World Trade
News headline image
What Does the Market Think About Illumina? ↗
 
Via Benzinga
News headline image
Illumina (ILMN) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Earnings Scheduled For July 31, 2025 ↗
 
Via Benzinga
News headline image
Cathie Wood's Ark Invest Loads Up On Coinbase, Roku, Illumina, And Bitmine Immersion ↗
Cathie Wood-led Ark Invest made significant trades in COIN, ROKU, ILMN, and BMNR. They also bought PD and SOFI, sold KTOS and RBLX. 
Via Benzinga
News headline image
Illumina (ILMN) Q2 EPS Jumps 9% ↗
Via The Motley Fool
News headline image
Why Illumina (ILMN) Shares Are Falling Today
Shares of genomics company Illumina (NASDAQ:ILMN) fell 6.1% in the afternoon session as investors reacted to its second-quarter earnings report, where a year-over-year revenue decline overshadowed... 
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
These Analysts Boost Their Forecasts On Illumina Following Upbeat Results ↗
 
Via Benzinga
News headline image
Illumina: A 5.2 Rating Amid Challenges and Opportunities ↗
Via The Motley Fool
News headline image
Illumina Inc (NASDAQ:ILMN) Q2 2025 Earnings: Mixed Results with Revenue Miss and EPS Beat ↗
Illumina's Q2 2025 earnings show mixed results: revenue missed estimates at $1.059B (-3% YoY), but EPS beat at $1.19. Shares dipped 1.18% post-report. 
Via Chartmill
News headline image
Illumina (NASDAQ:ILMN) Surprises With Q2 Sales
Genomics company Illumina (NASDAQ:ILMN) beat Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 3% year on year to $1.06 billion. Its non-GAAP profit of $0.36 per share was 64.4% below... 
Via StockStory
News headline image
Illumina (ILMN) To Report Earnings Tomorrow: Here Is What To Expect
Genomics company Illumina (NASDAQ:ILMN) will be reporting earnings this Thursday afternoon. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
News headline image
Illumina (ILMN) Stock Is Up, What You Need To Know
Shares of genomics company Illumina (NASDAQ:ILMN) jumped 3.7% in the pre-market session after analysts at Robert W. Baird increased their price target on the life sciences company's stock to $105.00.... 
Via StockStory
Topics Artificial Intelligence
News headline image
12 Analysts Assess Illumina: What You Need To Know ↗
 
Via Benzinga
News headline image
1 Profitable Stock with Exciting Potential and 2 We Question
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. 
Via StockStory
News headline image
Illumina Stock: What Went Wrong And Why It's Best To Stay Away ↗
According to the Adhishthana Principles, Illumina stock may remain under pressure for over 18 years — here's why. 
Via Benzinga
News headline image
Why Illumina (ILMN) Shares Are Falling Today
Shares of genomics company Illumina (NASDAQ:ILMN) fell 4.2% in the morning session after a Citi analyst downgraded the stock to 'Sell' from 'Neutral' and lowered the price target. 
Via StockStory
Topics Government World Trade
News headline image
Where Illumina Stands With Analysts ↗
 
Via Benzinga
News headline image
Illumina (ILMN) Stock Trades Down, Here Is Why
Shares of genomics company Illumina (NASDAQ:ILMN) fell 3.6% in the afternoon session after the major indices pulled back (Nasdaq -0.8%, S&P 500 -0.77%), largely due to escalating concerns surrounding... 
Via StockStory
Topics Artificial Intelligence Government Stocks
News headline image
iRhythm Technologies Announces Board Member Retirements and New Director Appointments
From iRhythm
Via GlobeNewswire
News headline image
5 Must-Read Analyst Questions From Illumina’s Q1 Earnings Call
Illumina’s first quarter results reflected ongoing challenges in the global genomics market, as the company’s performance fell short of market expectations, prompting a negative reaction from... 
Via StockStory
Topics Earnings World Trade
News headline image
“Mag 7 Undercard Movers: IBO, SNYR, CTOR, PNPN.V, LAB – Breakthroughs in Military Defense, Tech, Medical & Healthcare Fuel Market Buzz”
Via AB Newswire
Topics Artificial Intelligence
News headline image
SomaLogic Acquisition Marks Next Step In Illumina's Advanced Biomarker Push ↗
Illumina will acquire SomaLogic to expand in proteomics, adding new revenue streams and accelerating tech development in multiomics. 
Via Benzinga
News headline image
1 of Wall Street’s Favorite Stock to Target This Week and 2 to Brush Off
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
Topics Energy
News headline image
3 Reasons ILMN is Risky and 1 Stock to Buy Instead
What a brutal six months it’s been for Illumina. The stock has dropped 33.6% and now trades at $89.03, rattling many shareholders. This may have investors wondering how to approach the situation. 
Via StockStory
News headline image
Retail Investors Flock To Incyte As Drug Data, Qiagen Deal Fuel Optimism ↗
Stifel also upgraded the stock to ‘Buy’ with a $107 price target. 
Via Stocktwits
News headline image
Datadog To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Breaking Down Illumina: 11 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
3 Mid-Cap Stocks Walking a Fine Line
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.